Telephone
61.8.6555.2945
Address
Level 1 50 Angove Street North Perth, Western Australia (WA) 6006
Description
Botanix Pharmaceuticals Ltd. engages in the development of therapeutics for the treatment of skin diseases. It focuses on the treatment of patients battling with acne, psoriasis, and atoptic dermatitis. The firm also develops pharmaceutical ingredient known as cannabidol, which seeks to treat epilepsy, pain, arthritis, and schizophrenia. The company was founded by Roger New and Glen Travers in 1984 and is headquartered in North Perth, Australia.
Market Cap
PE
EV/EBITDA
DIV Yield
Franking
Ex Dividend Date (est.)
52 weeks range
Low 0.05 - 0.21
Trade Value (12mth)
AU$87,819.00
1 week
-6.06%
1 month
14.81%
YTD
198.08%
1 year
158.33%
All time high
163.333
EPS 3 yr Growth
-55.900%
EBITDA Margin
%
Operating Cashflow
-$12m
Free Cash Flow Return
-77.60%
ROIC
-58.90%
Interest Coverage
-155.20
Quick Ratio
5.70
Shares on Issue (Fully Dilluted)
1312m
HALO Sector
Healthcare
Next Company Report Date
22-Aug-24
Ex Dividend Date (est.)
N/A
Next Dividend Pay Date (est.)
N/A
Reporting Currency
AUD
Short Sell (% of issue)
0.00
Date | Announcements |
---|---|
31 October 23 |
September 2023 Quarterly Activities Report and Appendix 4C
×
September 2023 Quarterly Activities Report and Appendix 4C |
31 October 23 |
Investor Presentation and Investor Meetings
×
Investor Presentation and Investor Meetings |
31 October 22 |
A$5 million Institutional Placement and Share Purchase Plan
×
A$5 million Institutional Placement and Share Purchase Plan |
31 October 22 |
Proposed issue of securities - BOT
×
Proposed issue of securities - BOT |
31 October 22 |
Proposed issue of securities - BOT
×
Proposed issue of securities - BOT |
31 October 22 |
Proposed issue of securities - BOT
×
Proposed issue of securities - BOT |
31 July 23 |
June 2023 Quarterly Activities Report and Appendix 4C
×
June 2023 Quarterly Activities Report and Appendix 4C |
31 January 23 |
Appendix 4C - Quarterly
×
Appendix 4C - Quarterly |
31 January 23 |
Investor Presentation and Video
×
Investor Presentation and Video |
31 January 19 |
2019 Outlook Presentation
×
2019 Outlook Presentation |
31 August 23 |
2023 Annual General Meeting - Key Dates
×
2023 Annual General Meeting - Key Dates |
31 August 23 |
Appendix 4E Preliminary Final Report
×
Appendix 4E Preliminary Final Report |
31 August 22 |
Preliminary Final Report
×
Preliminary Final Report |
31 August 22 |
Trading Halt
×
Trading Halt |
31 August 20 |
Appendix 4E and Annual Report to Shareholders
×
Appendix 4E and Annual Report to Shareholders |
31 August 16 |
Appendix 4E and Annual Report to Shareholders
×
Appendix 4E and Annual Report to Shareholders |
30 September 13 |
Bone Medical Limited - Annual Report (BNE-AU)
×
Bone Medical Limited - Annual Report (BNE-AU) |
30 September 11 |
Annual Report (BNE-AU)
×
Annual Report (BNE-AU) |
30 November 22 |
Application for quotation of securities - BOT
×
Application for quotation of securities - BOT |
30 November 16 |
AGM Investor Presentation
×
AGM Investor Presentation |
30 November 16 |
Results of Annual General Meeting
×
Results of Annual General Meeting |
29 September 23 |
Appendix 4G and Corporate Governance Statement
×
Appendix 4G and Corporate Governance Statement |
29 September 23 |
Annual Report
×
Annual Report |
29 September 09 |
Annual Report (BNE-AU)
×
Annual Report (BNE-AU) |
29 September 06 |
Annual Report
×
Annual Report |
29 October 12 |
Bone Medical Limited - Notice of Annual General Meeting/Proxy Form (BNE-AU)
×
Bone Medical Limited - Notice of Annual General Meeting/Proxy Form (BNE-AU) |
29 October 10 |
Annual Report to shareholders (BNE-AU)
×
Annual Report to shareholders (BNE-AU) |
Load More
Load Less
Historical data
Forecasted data
Load More
Load Less
Historical data
Forecasted data
Load More
Load Less
Historical data
Forecasted data
Load More
Load Less
Percent of Issue
Value ($M)
Prior Change
7 Day Change
1 Month Change
3 Month Change
Access data on short interest, stock performance, and potential short-selling candidates across various markets to make informed decisions and optimize your trading strategies.
Unlock true investor intelligence
Research, trade and manage global markets from one place with HALO Global. It’s trading - the way you want it.
Get the latest insights and hot tips delivered right to your inbox
HALO Technologies Pty Ltd ABN 54 623 830 866 is a Corporate Authorised Representative No 1261916 of Macrovue Pty Ltd ABN 98 600 022 679 AFSL 484264. Macrovue Pty Ltd is a wholly owned subsidiary of HALO Technologies Pty Ltd.